Evercore Lowers Abbott Laboratories (NYSE:ABT) Price Target to $120.00

Abbott Laboratories (NYSE:ABT) had its price objective reduced by analysts at Evercore from $134.00 to $120.00 in a report issued on Friday,MarketScreener reports. The brokerage currently has an “outperform” rating on the healthcare product maker’s stock. Evercore’s price objective would indicate a potential upside of 23.85% from the stock’s current price.

A number of other research firms have also weighed in on ABT. Citigroup dropped their price objective on Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating for the company in a research note on Friday. Sanford C. Bernstein lowered their price target on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Jefferies Financial Group dropped their price target on shares of Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating for the company in a research report on Friday. Stifel Nicolaus decreased their price objective on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday. Finally, Wells Fargo & Company lowered their price objective on shares of Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating for the company in a research note on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $121.00.

Abbott Laboratories Stock Up 1.5%

ABT opened at $96.89 on Friday. Abbott Laboratories has a 12 month low of $93.92 and a 12 month high of $139.06. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. The business’s 50-day moving average price is $107.89 and its 200-day moving average price is $118.65. The company has a market cap of $168.75 billion, a P/E ratio of 27.14, a P/E/G ratio of 1.57 and a beta of 0.79.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.01. The company had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a return on equity of 17.71% and a net margin of 13.90%.Abbott Laboratories’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the business posted $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, equities analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Insiders Place Their Bets

In related news, VP John A. Jr. Mccoy sold 585 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $67,614.30. Following the transaction, the vice president owned 24,628 shares in the company, valued at $2,846,504.24. The trade was a 2.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $102,288.30. Following the completion of the transaction, the executive vice president directly owned 146,377 shares of the company’s stock, valued at approximately $16,918,253.66. The trade was a 0.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 3,055 shares of company stock valued at $353,097 over the last quarter. 0.46% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Cornerstone Financial Management LLC bought a new stake in shares of Abbott Laboratories during the fourth quarter valued at approximately $25,000. MidAtlantic Capital Management Inc. bought a new position in Abbott Laboratories in the fourth quarter worth $25,000. Purpose Unlimited Inc. purchased a new position in Abbott Laboratories during the fourth quarter valued at $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in shares of Abbott Laboratories during the 4th quarter valued at $26,000. Finally, Abound Financial LLC bought a new position in shares of Abbott Laboratories in the 4th quarter worth about $26,000. Institutional investors own 75.18% of the company’s stock.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Preliminary settlement reached in six shareholder derivative suits tied to Abbott’s U.S. infant‑formula business, reducing litigation overhang for investors. Read More.
• Positive Sentiment: New data on Cancerguard MCED (multi‑cancer early detection) presented at AACR 2026 — important for Abbott’s growth thesis since the Exact Sciences deal expanded its oncology diagnostics exposure. Continued clinical progress supports longer‑term revenue upside. Read More.
• Positive Sentiment: Insiders added roughly $3.1M of stock, and a number of analysts still see upside — some calling the post‑acquisition pullback a buying opportunity given valuation and Abbott’s dividend track record. Read More. Read More.
• Neutral Sentiment: Q1 results: adjusted EPS $1.15 (vs. $1.14 est.) and revenue $11.16B (vs. $10.99B); company set FY 2026 adjusted EPS guidance to $5.38–$5.58 and Q2 guide to $1.25–$1.31, explicitly including ~$0.20 of dilution from the Exact Sciences acquisition. Investors are parsing beat vs. the guidance change. Read More.
• Neutral Sentiment: Earnings call transcript and analyst commentary emphasize medical‑device strength offset by Diagnostics/Nutrition softness and acquisition-related margin pressure — useful for active traders but mixed for near‑term stock direction. Read More.
• Negative Sentiment: Market reaction: shares fell after the print because Abbott trimmed guidance and flagged Nutrition weakness and margin compression; coverage shows the takeover (≈$21–23B) is dilutive near term. Read More.
• Negative Sentiment: Many brokers lowered price targets and some cut forecasts following Q1/guidance — several firms kept positive ratings but reduced targets (examples include RBC, Jefferies, Raymond James, Citi and others), amplifying short‑term selling pressure. Read More.
• Negative Sentiment: Analyst notes and headlines highlighted the EPS guidance cut and Nutrition slump as primary reasons for the earlier drop — these remain catalysts to watch for the next quarter. Read More.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.